COBRA and Prescription Drug Coverage Continuity

COBRA continuation coverage preserves access to the same health plan benefits that were active at the time of a qualifying event — and for most group health plans, that includes prescription drug coverage. This page examines how drug benefits carry forward under COBRA, the regulatory framework governing that continuity, and the practical decision points that arise when comparing COBRA drug coverage against alternative options.

Definition and scope

Under the Consolidated Omnibus Budget Reconciliation Act of 1985 (COBRA), codified at 29 U.S.C. §§ 1161–1168, qualified beneficiaries are entitled to elect "coverage under the plan" that is identical to the coverage available to similarly situated active employees. Because prescription drug benefits are typically structured as a component of a group health plan — not as a standalone policy — they fall squarely within that entitlement.

The scope of this continuity rule is broad. It applies whether the prescription drug benefit is integrated into a major medical plan (a common arrangement with tiered formularies), bundled into a high-deductible health plan paired with an HSA, or administered through a separate pharmacy benefit manager (PBM) contract that the employer has embedded in the plan. The Department of Labor (DOL) and the Internal Revenue Service (IRS) jointly oversee COBRA compliance, and both agencies treat the pharmacy benefit as inseparable from the broader plan structure when that benefit is offered to active employees.

A clearer understanding of the full regulatory environment — including which plans are subject to COBRA and which are exempt — is available at /regulatory-context-for-cobra-administration.

How it works

When a qualifying event occurs and a beneficiary elects COBRA, the pharmacy benefit continues under the same terms that applied to active employees on that date. That means the same formulary tiers, the same cost-sharing structure (copayments, coinsurance, deductible accumulation), and the same utilization management requirements — prior authorization, step therapy protocols, quantity limits — remain in effect.

The mechanics operate in three phases:

1. Election and enrollment: The qualified beneficiary elects COBRA within the 60-day election window established by 29 U.S.C. § 1165(1). Upon valid election and timely premium payment, coverage is retroactive to the day after the qualifying event, preventing any gap in pharmacy benefit access.

2. Ongoing premium payment: COBRA premiums may not exceed 102 percent of the applicable cost of coverage, per 26 U.S.C. § 4980B(f)(2)(C). For plans where the pharmacy benefit represents a significant portion of total plan cost — particularly plans covering specialty medications — this can translate to substantial monthly out-of-pocket premiums.

3. Plan changes and formulary updates: If the employer's plan modifies its formulary, adjusts tier placement, or changes PBM contracts during the COBRA coverage period, those same changes apply to the COBRA participant. The employer is not required to freeze the formulary at the date of election. The DOL has confirmed through guidance that COBRA beneficiaries receive "the same coverage" that similarly situated active employees receive on any given date, not necessarily the coverage that existed at the time of the qualifying event.

Common scenarios

Specialty medication dependency: A beneficiary managing a chronic condition — such as rheumatoid arthritis or multiple sclerosis — who relies on a Tier 4 or Tier 5 specialty drug may face monthly COBRA premiums that, when added to specialty drug cost-sharing, exceed the cost of alternative coverage. The formulary continuity guarantees that any existing prior authorization approval transfers seamlessly to the COBRA period without requiring re-authorization solely due to the qualifying event, though the plan's standard re-authorization schedule still applies.

Mid-year formulary changes: If an employer switches PBMs at plan renewal — a change that occurs within the COBRA coverage period — the new formulary governs. A medication that was previously covered at Tier 2 might shift to Tier 3 or require step therapy under the new PBM arrangement. COBRA participants have no right to remain on a prior formulary solely on the basis of their COBRA status.

High-deductible health plan (HDHP) with integrated pharmacy benefit: For participants who elected an HDHP before the qualifying event, COBRA continuation preserves the integrated structure. Prescription drug costs continue to apply toward the plan deductible before cost-sharing begins, consistent with IRS rules governing HSA-compatible plans (IRS Notice 2004-2).

Medicare and COBRA overlap: When a beneficiary becomes entitled to Medicare and elects COBRA secondarily, the interaction between Medicare Part D (prescription drug coverage) and the COBRA drug benefit requires careful coordination. Medicare Part D is a primary payer for drug claims in certain circumstances, and maintaining a COBRA plan with creditable drug coverage alongside Part D can create coordination complexities. The Centers for Medicare & Medicaid Services (CMS) governs Medicare Secondary Payer rules in this context.

For a broader overview of COBRA options and how they compare to marketplace alternatives, the /index page provides navigational access to the full subject hierarchy.

Decision boundaries

Choosing COBRA primarily for prescription drug continuity — rather than for broader medical coverage — involves a structured set of comparisons:

COBRA vs. ACA Marketplace plan with drug coverage: Marketplace plans are required under 42 U.S.C. § 18022 to cover prescription drugs as an essential health benefit, but the specific formulary will differ from the employer plan. A beneficiary with an established specialty drug authorization on an employer plan may face a new prior authorization process on a marketplace plan, creating a potential coverage gap for that medication.

Integrated vs. standalone drug benefit: Some employer plans carve out the pharmacy benefit to a separate administrative entity. In a carved-out arrangement, COBRA election covers both the medical and the pharmacy components as long as both were offered to active employees. If the employer offers the pharmacy benefit as a genuinely separate, optional election, a beneficiary must evaluate whether electing only the pharmacy COBRA — without medical — satisfies the plan's eligibility structure.

Continuation duration: COBRA drug coverage lasts for the same maximum period as the overall COBRA election — 18 months for most termination and reduction-in-hours qualifying events, or 36 months for divorce, dependent loss of status, and similar events (29 U.S.C. § 1162). An 11-month disability extension applies when the Social Security Administration has made a disability determination within the first 60 days of COBRA coverage.

Cost comparison benchmark: Because COBRA premiums cover the full actuarial cost of the plan plus the 2 percent administrative fee, beneficiaries who use minimal medical services but high-cost medications should compare the total annual COBRA premium against the combined cost of a lower-premium marketplace plan plus out-of-pocket drug costs under that plan's formulary. No single formula governs this trade-off; it depends on the specific medications, tier placements, and plan deductible structures involved.

References

• Department of Labor, Employee Benefits Security Administration — COBRA Continuation Coverage
• 29 U.S.C. §§ 1161–1168 — COBRA Statutory Text (House of Representatives Office of the Law Revision Counsel)
• 26 U.S.C. § 4980B — Excise Tax on Failure to Meet Continuation Coverage Requirements (IRS)
• IRS Notice 2004-2 — HSA Guidance, Q&A on HDHP and Prescription Drug Coverage
• Centers for Medicare & Medicaid Services — Medicare Secondary Payer Overview
• 42 U.S.C. § 18022 — Essential Health Benefits Requirements (House of Representatives Office of the Law Revision Counsel)

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)